NeoDynamics Informe acción OM:NEOD Capitalización de mercado
SEK 29.4m
Finanzas de la empresa + 1 Analista
NeoDynamics AB (publ)
Informe acción OM:NEOD
Capitalización de mercado: SEK 29.4m
This company listing is no longer active This company may still be operating, however this listing is no longer active. Find out why through their latest events.
See Latest Events Resumen de acción NEOD NeoDynamics AB (publ), empresa de tecnología médica, se dedica al desarrollo de sistemas de biopsia para mejorar el diagnóstico y el tratamiento de pacientes con cáncer de mama.
Recompensas Análisis de riesgos + 2 riesgos adicionales
Ver todos los controles de riesgos Competidores de NeoDynamics AB (publ) Historial de precios y rendimiento
Resumen de todos los máximos históricos, cambios y caídas de precios de NeoDynamics Precios históricos de las acciones Precio actual de la acción SEK 0.90 Máximo en las últimas 52 semanas SEK 25.00 Mínimo de 52 semanas SEK 0.71 Beta 1.24 1Cambio en 1 mes -0.66% Variación en 3 meses -5.06% Cambio de 1 año -95.26% 3Variación en 3 años -99.66% Variación en 5 años -99.80% Variación desde la OPV -99.82%
Noticias y actualizaciones recientes Nasdaq Stockholm AB Decides the Shares in NeoDynamics Shall Be Given Observation Status May 17
First quarter 2024 earnings released: kr0.058 loss per share (vs kr19.28 loss in 1Q 2023) May 08
Full year 2023 earnings released: kr30.21 loss per share (vs kr62.00 loss in FY 2022) Feb 21 NeoDynamics AB (publ) to Report Nine Months, 2024 Results on Nov 19, 2024
Insufficient new directors Feb 13
NeoDynamics AB (publ) Announces CFO Aaron Wong to Leave by End of May 2024 Dec 14 Ver más actualizaciones Nasdaq Stockholm AB Decides the Shares in NeoDynamics Shall Be Given Observation Status May 17
First quarter 2024 earnings released: kr0.058 loss per share (vs kr19.28 loss in 1Q 2023) May 08
Full year 2023 earnings released: kr30.21 loss per share (vs kr62.00 loss in FY 2022) Feb 21 NeoDynamics AB (publ) to Report Nine Months, 2024 Results on Nov 19, 2024
Insufficient new directors Feb 13
NeoDynamics AB (publ) Announces CFO Aaron Wong to Leave by End of May 2024 Dec 14
Neodynamics Launches Device Registry in Germany, Cost-Effective Collection of Real-World Data Dec 12
New major risk - Shareholder dilution Aug 23 NeoDynamics AB (publ) has completed a Composite Units Offering in the amount of SEK 72.30071 million. Aug 22
Second quarter 2023 earnings released: kr0.22 loss per share (vs kr0.17 loss in 2Q 2022) Aug 06
Neodynamics AB Presents Results of Pulse Study At the Annual Congress of the German Society of Senology, Munich Jul 11
NeoDynamics AB Presents Final Data Set from NeoDynamics' Pulse Study Presented at the SBI Breast Imaging Symposium May 06
Full year 2022 earnings released: kr0.76 loss per share (vs kr1.14 loss in FY 2021) Feb 19 NeoDynamics AB (publ) to Report Fiscal Year 2023 Results on Feb 16, 2024
NeoDynamics Announces Changes to Board of Directors Feb 15
NeoDynamics Appoints Matthew Colpoys, to Lead US Operations Dec 02
Third quarter 2022 earnings released: kr0.12 loss per share (vs kr0.22 loss in 3Q 2021) Nov 19
Price target decreased to kr1.10 Nov 16
NeoDynamics AB (publ) Appoints Brendan Carney as National Sales Director Nov 09
Neodynamics AB (Publ) Launches Neonavia Biopsy System Configured with Its Flexipulse Probe in the United States to Support the Diagnosis of Cancer Oct 26
NeoDynamics AB (publ) to Report Q3, 2022 Results on Nov 17, 2022 Oct 08
NeoDynamics Receives Approval for Its Innovative Pulse Biopsy System Neonavia® from the US Food and Drug Administration, FDA Sep 09
Second quarter 2022 earnings released: kr0.17 loss per share (vs kr0.30 loss in 2Q 2021) Aug 19
Neodynamics AB (Publ) Receives Ethical Approval for German Device Registry Jul 07
Gryningskust Holding AB acquired additional 14.0 % minority stake in NeoDynamics AB (publ) (OM:NEOD). Jun 18
NeoDynamics AB (publ) Announces Update on the FDA approval process for NeoNavia Jun 09
First quarter 2022 earnings released: kr0.28 loss per share (vs kr0.29 loss in 1Q 2021) May 14
NeoDynamics AB (publ) to Report Q1, 2022 Results on May 12, 2022 Apr 14
NeoDynamics Files a Registration Application for Its Innovative Pulse Biopsy System NeoNavia in the U.S Mar 02
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 18
NeoDynamics AB (publ) to Report Fiscal Year 2021 Results on Feb 16, 2022 Feb 16
NeoDynamics AB to Present Results from the Pulse Study Illustrating the Benefits of the Novel Biopsy Device NeoNavia in Challenging Axillary Lymph Nodes, At the SBI/ACR Breast Imaging Symposium in Savannah, Georgia Jan 20
Third quarter 2021 earnings released: kr0.22 loss per share (vs kr0.19 loss in 3Q 2020) Nov 18
Neodynamics Grants A U.S. Patent for Its Biopsy Needle Aug 26
Second quarter 2021 earnings released: kr0.30 loss per share (vs kr0.18 loss in 2Q 2020) Aug 21
CFO & Head of Investor Relations Jorgen Vrenning has left the company Jun 08
First quarter 2021 earnings released: kr0.29 loss per share (vs kr0.41 loss in 1Q 2020) May 21
NeoDynamics AB Presents an Abstract on Pulse Biopsy Data for NeoNavia at the UK Association of Breast Surgeons Conference 2021 May 18
Is NeoDynamics (NGM:NEOD) In A Good Position To Invest In Growth? Mar 18
New 90-day low: kr3.00 Feb 22
Full year 2020 earnings released: kr0.52 loss per share (vs kr1.24 loss in FY 2019) Feb 20
New 90-day low: kr3.38 Feb 03
New 90-day low: kr3.60 Jan 19
NeoDynamics Will Be Granted Another European Patent for Its Pulse Biopsy Tools Jan 14
New 90-day low: kr3.75 Dec 18
Insider recently sold kr423k worth of stock Dec 11
NeoDynamics AB (publ) (NGM:NEOD) Insiders Increased Their Holdings Dec 03
Third quarter 2020 earnings released: kr0.19 loss per share Nov 20
NeoDynamics AB (Publ) Wins First UK Order of Pulse Biopsy System Neonavia Nov 19
NeoDynamics AB (publ) Enters A Scientific Partnership to Evaluate Its Technology Platform in Osteoarthritis Nov 12
NeoDynamics AB (publ) Announces Executive Changes Nov 03
NeoDynamics AB (publ) Ready to Launch the New Pulse Biopsy System NeoNavia Sep 26
New 90-day high - kr3.49 Sep 09
Earnings released Aug 22
New 90-day high - kr3.37 Aug 12 Rentabilidad de los accionistas NEOD SE Medical Equipment Mercado SE 7D -1.1% -0.9% 0.6% 1Y -95.3% 4.6% 22.5%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: Los resultados de NEOD fueron inferiores a los de la industria Swedish Medical Equipment, que obtuvo un rendimiento del 4.6% el año pasado.
Rentabilidad vs. Mercado: NEOD obtuvo unos resultados inferiores a los del mercado Swedish, que fueron del 22.5% el año pasado.
Volatilidad de los precios Is NEOD's price volatile compared to industry and market? NEOD volatility NEOD Average Weekly Movement 15.4% Medical Equipment Industry Average Movement 6.7% Market Average Movement 5.5% 10% most volatile stocks in SE Market 11.0% 10% least volatile stocks in SE Market 3.2%
Precio estable de las acciones: NEOD no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de NEOD(15%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de Swedish.
Acerca de la empresa NeoDynamics AB (publ), empresa de tecnología médica, se dedica al desarrollo de sistemas de biopsia para mejorar el diagnóstico y el tratamiento de pacientes con cáncer de mama. Desarrolla NeoNavia, un sistema de biopsia que ofrece a médicos y pacientes muestras de tejido con un alto rendimiento tisular para un diagnóstico correcto y un tratamiento individualizado. NeoDynamics AB (publ) se constituyó en 2015 y tiene su sede en Lidingö (Suecia).
Mostrar más Resumen de fundamentos de NeoDynamics AB (publ) ¿Cómo se comparan los beneficios e ingresos de NeoDynamics con su capitalización de mercado? Estadísticas fundamentales de NEOD Capitalización bursátil SEK 29.35m Beneficios(TTM ) -SEK 87.19m Ingresos (TTM ) SEK 757.51k
38.7x Ratio precio-ventas (PS)
-0.3x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de NEOD Ingresos SEK 757.51k Coste de los ingresos SEK 1.50m Beneficio bruto -SEK 740.94k Otros gastos SEK 86.45m Beneficios -SEK 87.19m
Últimos beneficios comunicados
Mar 31, 2024
Próxima fecha de beneficios
Aug 20, 2024
Beneficios por acción (BPA) -2.67 Margen bruto -97.81% Margen de beneficio neto -11,509.57% Ratio deuda/patrimonio 0%
¿Cómo se ha desempeñado NEOD a largo plazo?
Ver rendimiento histórico y comparativa
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
